Human and murine macrophages mediate activation of MEN 4901/T-0128: A new promising camptothecin analogue-polysaccharide conjugate

Anti-Cancer Drugs

Volumn 17, Issue 10, 2006, Pages 1119-1126

  Binaschi, Monica ^a,b   Parlani, Massimo ^a   Bellarosa, Daniela ^a   Bigioni, Mario ^a   Salvatore, Carmela ^a   Palma, Carla ^a   Crea, Attilio ^a   Maggi, Carlo Alberto ^a   Manzini, Stefano ^a   Goso, Cristina ^a  

^a Menarini Ricerche Pomezia ^*  (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Cathepsin B; Macrophages; MEN 4901 T 0128; Phagocytosis; Tumour targeting

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CATHEPSIN B; MEN 4901; PHORBOL 13 ACETATE 12 MYRISTATE; POLYSACCHARIDE; T 0128; T 1028; T 2513; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONJUGATE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYSOSOME; MACROPHAGE; MOUSE; NONHUMAN; PH; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; CAMPTOTHECIN; CATHEPSIN B; CELLS, CULTURED; DEXTRANS; HUMANS; IMMUNITY, CELLULAR; MACROPHAGES; MICE; MODELS, BIOLOGICAL; PHAGOCYTOSIS; POLYSACCHARIDES; PRODRUGS; TOPOTECAN;

EID: 33750564495     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000236307.20339.b4     Document Type: Article

References (19)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85:271-291.
2. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33:245-259.
3. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, et al. Complete regression of xenografted human carcinomas by camptothecin analogue- carboxymethyl dextran conjugates (T-0128). Cancer Res 2000; 60:2988-2995.
4. Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J Control Release 2000; 69:399-412.
5. Otto HH, Schirmeister T. Cysteine proteases and their inhibitors. Chem Rev 1997; 97:133-172.
6. Qian F, Chan SJ, Gong Q, Bajkowski AS, Steiner DF, Frankfater A. The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors. Biomed Biochim Acta 1991; 50:531-540.
7. United Kingdom Co-ordinating Commitee on Cancer Research (UKCCCR). Guidelines for the welfare of animals in experimental neoplasia (Second Edition). Br J Cancer 1998; 77:1-10.
8. Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of active cathepsin B. Enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem 1999; 264:100-109.
9. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH effects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54:6517-6525.
10. Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL, et al. Fluorescent microplate assay for cancer cell-associated cathepsin B. Eur J Biochem 2000; 267:4165-4170.
11. Sloane BF, Dunn JR, Honn KV. Lysosomal cathepsin B: correlation with metastatic potential. Science 1981; 212:1151-1153.
12. Konduri S, Lakka SS, Tasiou A, Yanamandra N, Gondi CS, Dinh DH, et al. Elevated levels of cathepsin B in human glioblastoma cell lines. Int J Oncol 2001; 19:519-524.
13. Tzanakakis GN, Margioris AN, Tsatsakis AM, Vezeridis MP. The metastatic potential of human pancreatic cell lines in the liver of nude mice correlates well with cathepsin B activity. Int J Gastrointest Cancer 2003; 34:27-38.
14. Staack A, Tolic D, Kristiansen G, Schnorr D, Loening SA, Jung K. Expression of cathepsin B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology 2004; 63:1089-1094.
15. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Expression of cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer 2004; 40:1610-1616.
16. Redwood SM, Liu BC,Weiss RE, Hodge DE, Droller MJ. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 1992; 69:1212-1219.
17. Harada M, Imai J, Okuno S, Suzuki T. Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128) possible cellular mechanism for antitumor activity. J Control Release 2000; 69:389-397.
18. Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003; 83:1555-1567.
19. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-265.